首页(Home)
品牌专区(Brands-parters)
//自动完成提示
function beginSearch() {
if (document.getElementById("Keyword").value.replace(/(^\s*)|(\s*$)/g, "").length > 2) {
$("#divMsg").html("");
var tbSearch = document.getElementById("Keyword").value;
var div_msg = document.getElementById("divMsg");
div_msg.style.display = "block";
$.ajax({
type: "post",
dataType: "json", //数据格式:JSON
url: "/tools/submit_ajax.ashx?action=zhitishi",
data: { father: tbSearch },
async: false,
success: function (data) {
var str = "";
var str1 = "";
var str2 = "";
var str3 = "";
var SupplyType = data.SupplyType; //供应品类列表
var Brands = data.Brands; //品牌列表
var ProductStyle = data.ProductStyle; //产品列表
var str0 = "";
if (SupplyType != null && SupplyType != "") {
str0 += " 美国 NeuroSigma www.neurosigma.com Deep Brain Stimulation (DBS) - Pioneered in France for the treatment of essential tremor and Parkinson’s disease. New therapies in development by NeuroSigma. Trigeminal Nerve Stimulation (TNS) - A proprietary therapy developed at the University of California, Los Angeles and exclusively licensed to NeuroSigma. CAUTION: The TNS and DBS therapies being developed by NeuroSigma are investigational therapies and limited by United States law for investigational use.
位于加利福尼亚州洛杉矶市的NeuroSigma公司的新产品——Monarch外部三叉神经激发(eTNS)系统已经通过欧盟批准。在产品发布会上,该公司把它被定义为9岁及以上癫痫和抑郁症患者的辅助治疗系统。
NeuroSigma, Inc. is a medical device company based in Westwood, California. NeuroSigma has a growing pipeline of treatments targeting epilepsy, depression, post-traumatic stress disorder (PTSD), obesity, among others and is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I and Phase II clinical trials. NeuroSigma is utilizing two distinct therapy platforms: